Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chitra Hosing

Showing results (221-230 of 234) with videos related to

Pageof 24
Sort By:
The Lancet. Haematology|March 27, 2019
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trialQaiser Bashir, Peter F Thall, Denái R Milton, et al.
Haematologica|May 6, 2021
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysisYago Nieto, Stephen Gruschkus, Benigno C Valdez, et al.
The New England Journal of Medicine|December 14, 2012
Cord-blood engraftment with ex vivo mesenchymal-cell cocultureMarcos de Lima, Ian McNiece, Simon N Robinson, et al.
Bone Marrow Transplantation|February 15, 2024
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxisAlexandre E Malek, Taha Al-Juhaishi, Denái R Milton, et al.
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Nature Medicine|April 4, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Blood Advances|July 15, 2021
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicityUri Greenbaum, Paolo Strati, Rima M Saliba, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Blood Cancer Journal|March 28, 2026
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromesAlexandre Bazinet, Alex Bataller, Kelly Chien, et al.
The Journal of Clinical Investigation|August 3, 2016
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsPartow Kebriaei, Harjeet Singh, M Helen Huls, et al.
Pageof 24

Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
The Lancet. Haematology|March 27, 2019
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trialQaiser Bashir, Peter F Thall, Denái R Milton, et al.
Haematologica|May 6, 2021
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysisYago Nieto, Stephen Gruschkus, Benigno C Valdez, et al.
The New England Journal of Medicine|December 14, 2012
Cord-blood engraftment with ex vivo mesenchymal-cell cocultureMarcos de Lima, Ian McNiece, Simon N Robinson, et al.
Bone Marrow Transplantation|February 15, 2024
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxisAlexandre E Malek, Taha Al-Juhaishi, Denái R Milton, et al.
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Nature Medicine|April 4, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Blood Advances|July 15, 2021
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicityUri Greenbaum, Paolo Strati, Rima M Saliba, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Blood Cancer Journal|March 28, 2026
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromesAlexandre Bazinet, Alex Bataller, Kelly Chien, et al.
The Journal of Clinical Investigation|August 3, 2016
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsPartow Kebriaei, Harjeet Singh, M Helen Huls, et al.
Pageof 24